Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell fas-FasL-Dependent AICD

Cancer Immunology Research

Volumn 3, Issue 4, 2015, Pages 368-379

  Kuünkele, Annette ^a   Johnson, Adam J ^a   Rolczynski, Lisa S ^a   Chang, Cindy A ^a   Hoglund, Virginia ^a   Kelly Spratt, Karen S ^a   Jensen, Michael C ^a,b,c  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD3 ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; FAS ANTIGEN; FAS LIGAND; GRANZYME B; KI 67 ANTIGEN; L SELECTIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; FASLG PROTEIN, HUMAN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACTIVATION INDUCED CELL DEATH; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PILOT STUDY; T LYMPHOCYTE ACTIVATION; TUMOR CELL; ANIMAL; BRAIN NEOPLASMS; CYTOTOXICITY; DRUG SCREENING; EVALUATION STUDY; GENE VECTOR; GENETICS; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; NEUROBLASTOMA; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GENETIC VECTORS; HUMANS; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE, INBRED NOD; MICE, SCID; NEUROBLASTOMA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944042104     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0200     Document Type: Article

References (41)

1. Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Trans Immunol 2014; 3:e16.
2. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
4. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-9.
5. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294-305.
6. + T cells in immunodeficient mice. Blood 2011;117:1888-98.
7. + T cells derived from virus-specific central memory T cells. Blood 2012;119:72-82.
8. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 2014;41:116-26.
9. + central memory T cells manufactured at clinical scale. J Immunother 2012;35:689-701.
10. Leuci V, Mesiano G, Gammaitoni L, Aglietta M, Sangiolo D. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Curr Gene Ther 2014;14:52-62.
11. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014;257:107-26.
12. Moritz D, Groner B. Aspacer region between thesinglechain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995;2:539-46.
13. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008;180: 7028-38.
14. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015;3:125-35.
15. Schonmann SM, Iyer J, Laeng H, Gerber HA, Kaser H, Blaser K. Production and characterization of monoclonal antibodies against human neuroblastoma. Int J Cancer 1986;37:255-62.
16. Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004;6:704-11.
17. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15: 825-33.
18. d'Uscio C, Blaser K. Establishment of anti-human neuroblastoma-selective isotype-switch variants. J Immunol Methods 1992;146:63-70.
19. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013;19:3153-64.
20. Ausubel LJ, Hall C, Sharma A, Shakeley R, Lopez P, Quezada V, et al. Production of CGMP-grade lentiviral vectors. BioProcess Int 2012;10: 32-43.
21. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011;118: 1255-63.
22. Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N. Mechanism of activation-induced cell death of T cells and regulation of Fas L expression. Crit Rev Immunol 2014;34:301-14.
23. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007;18:712-25.
24. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014;257: 127-44.
25. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014;257:91-106.
26. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98.
27. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/ CD28 receptor. Nat Biotechnol 2002;20:70-5.
28. Campana D, Schwarz H, Imai C. 4-1BB chimeric antigen receptors. Cancer J 2014;20:134-40.
29. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013;1:43-53.
30. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101:1637-44.
31. Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol 2007;35:1388-97.
32. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9: 279-86.
33. James JR, Vale RD. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 2012;487:64-9.
34. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013;2:e105.
35. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther 2010;17:1206-13.
36. Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol 1997;159:3156-67.
37. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
38. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappa B inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001;21:3964-73.
39. Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 1998;8:461-71.
40. Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008;181:4832-9.
41. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.